Cannabis use disorder (CUD) occurs frequently in patients with schizophrenia (SCZ) and worsens the course of this severe psychiatric disorder. Treatments available for these ?dual diagnosis? patients are inadequate. New treatments to limit cannabis use in patients with schizophrenia are sorely needed. We have proposed that a dysregulated mesocorticolimbic ?brain reward circuit? (BRC) in patients with SCZ underpins their cannabis use, and that cannabis use ameliorates this dysregulated circuitry. Studying the neural effects of a monetary probe linked to fMRI, as well as a behavioral measure of reward responsiveness, we and others have demonstrated that patients with SCZ do indeed have a deficit within their BRC and decreased reward responsiveness, as compared to normal subjects. Moreover, pilot data from our ARRA- funded grant involving resting state functional connectivity (RSC) suggest that such patients also have decreased intrinsic inter-regional synchronization within the BRC. Lastly, our pilot imaging data further indicate that both cannabis, as well as the cannabinoid agonist dronabinol, decrease the dysfunctional BRC deficit, as assessed by a monetary probe linked to fMRI and by resting state functional connectivity. In this proposal, we seek to confirm and expand upon our ARRA-funded investigation.
The first aim i s to assess the status of the BRC in patients with SCZ and co-occurring CUD (SCZ-CUD), as well as in those with SCZ (without CUD) and CUD (without SCZ): (1a) To confirm that (i) task-related fMRI activity linked to a monetary brain reward probe; (ii) inter-regional resting state functional connectivity; and (iii) a behavioral measure of reward responsiveness, will be decreased in patients with SCZ-CUD as compared to healthy controls; and (1b) to explore these measures in those with SCZ (without CUD) and with CUD (without SCZ).
The second aim will assess the effect of cannabis and dronabinol on BRC in patients with SCZ- CUD and in those with CUD (without SCZ): (2a) To confirm whether dysfunctional (i) task-related fMRI activity linked to a monetary brain reward probe, and (ii) inter-regional resting state functional connectivity will be ameliorated; and (2b) to explore whether a behavioral measure of reward responsiveness will be improved in patients with SCZ-CUD, and (2c) to explore these measures in those with CUD (without SCZ), and to compare the results to those from (2a).
The third aim will assess other effects of dronabinol in patients with SCZ-CUD -- on craving, mood, negative symptoms, psychotic symptoms and cognition. By probing BRC dysregulation and testing the effects of smoked cannabis on this dysregulation, this study will help further elucidate whether ?self-medication? of a BRC deficit may be an important component of cannabis use in patients with SCZ. Moreover, by probing the physiological and behavioral effects of dronabinol, this research can lead to development of therapeutic agents, potentially including dronabinol, other cannabinoids or non-cannabinoid agents that may ameliorate a BRC deficiency and thus limit cannabis use in these patients.

Public Health Relevance

Public health relevance: Cannabis use disorder, which is common in patients with schizophrenia, worsens the course of this severe psychiatric disorder. This study seeks to establish that cannabis is used for ?self- medication? by these patients because it ameliorates a deficit in their brain circuitry, and further, that dronabinol, an orally administered drug approved for certain medical conditions, can also ameliorate this deficit. If dronabinol can be shown to safely ameliorate the brain reward circuit deficit in these patients, it should be tested as a potential treatment to limit cannabis use, and thereby reduce adverse outcomes, in patients with schizophrenia.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
6R01DA034699-05
Application #
9832832
Study Section
Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section (NPAS)
Program Officer
Lin, Yu
Project Start
2013-09-15
Project End
2020-03-31
Budget Start
2018-11-01
Budget End
2019-03-31
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Dartmouth-Hitchcock Clinic
Department
Type
DUNS #
150883460
City
Lebanon
State
NH
Country
United States
Zip Code
03756
Khokhar, Jibran Y; Dwiel, Lucas L; Henricks, Angela M et al. (2018) The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophr Res 194:78-85
Akerman, Sarah C; Brunette, Mary F; Green, Alan I et al. (2015) Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review. J Subst Abuse Treat 52:40-7
Fischer, Adina S; Whitfield-Gabrieli, Susan; Roth, Robert M et al. (2015) Response to ""cortico-accumbens circuitry in schizophrenia: merely a reward system?"" by Rolland and Jardri (SCHRES-14-D-00731). Schizophr Res 161:519
Akerman, Sarah C; Brunette, Mary F; Noordsy, Douglas L et al. (2014) Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders. Curr Addict Rep 1:251-260
Fischer, Adina S; Whitfield-Gabrieli, Susan; Roth, Robert M et al. (2014) Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC. Schizophr Res 158:176-82